21/04/2026 Phase 3 LITESPARK-012: Triplet and Doublet Regimens Fail to Surpass KEYTRUDA + LENVIMA in Advanced RCC Phase 3 LITESPARK-012: Triplet and Doublet Regimens Fail to Surpass KEYTRUDA + LENVIMA in Advanced RCC ( Ref ) Merck & Co. and Eisai announced that their Phase 3 LITESPARK-012 trial did not meet its dual primary endpoints of progression-free survival (PFS) and overall survival (OS) for first-line treatment of advanced clear cell RCC. Both experimental combination

October 5th Week, 2025 Regulatory Events 🎯 The EC approved Merck & Co./ MSD 's pembrolizumab (anti-PD-1) single agent as a neoadjuvant Tx followed by adjuvant pembrolizumab + RT ± cisplatin after surgery, and then as a single agent for adults with resectable LA SCCHN with PD-L1 CPS ≥1. (Ref 1) ❓ How is this approval expected to impact the treatment algorithm of LA SCCHN? Clinical Events 🔬 Merck & Co./ MSD and Eisai US reported that the Phase 3 LITESPARK-011 trial of b

Thyroid Cancer, despite a good prognosis, has been a cause of concern over the past years. Thyroid Cancer shows no symptoms in the early stage, but its increasing rate of occurrence indicates the need for further diagnostic and therapeutic options. In observance of Thyroid Cancer Awareness month, Oncofocus is pleased to present an infographic highlighting the key options with a glimpse of the emerging therapies in the Thyroid cancer treatment paradigm.